pantoprazole has been researched along with famotidine in 26 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 3 (11.54) | 18.2507 |
| 2000's | 11 (42.31) | 29.6817 |
| 2010's | 10 (38.46) | 24.3611 |
| 2020's | 2 (7.69) | 2.80 |
| Authors | Studies |
|---|---|
| Bräuer, U; Kromer, W; Postius, S | 1 |
| Berstad, A; Hatlebakk, JG | 1 |
| Martin, P; McKeand, W; Ohning, G; Paul, J; Pisegna, JR; Walsh, JH | 1 |
| Allen, DG; Bersenas, AM; Conlon, PD; Mathews, KA | 1 |
| Bozkurt, B; Demirkan, K; Kalyoncu, AF; Karakaya, G | 1 |
| Esplugues, JV; Martí-Cabrera, M; Ponce, J | 1 |
| Choi, SK; Jeong, HK; Jun, CH; Kim, HI; Kim, HS; Lee, GH; Park, CH; Rew, JS | 1 |
| Gerber, DR; Ojiako, K; Schorr, C; Shingala, H | 1 |
| Andhavarapu, S; Baker, L; Carlson, RW | 1 |
| Lwin, AA | 1 |
| Lin, HJ; Tsai, JJ | 1 |
| Antonioli, L; Blandizzi, C; Colucci, R; Del Tacca, M; Fornai, M; Ghisu, N; Tuccori, M | 1 |
| Adkison, KK; Gross, AS; Humphreys, JE; Koo, SH; Lee, DY; Lee, EJ; Li, L; Lou, Y; Mehta, AA; Polli, JW; Vaidya, SS | 1 |
| Chan, P; Chu, WM; Kng, C; Kwan, A; Lam, KF; Lau, YK; Ling, YH; Ng, FH; Wong, BC; Wong, SY; Yuen, WC | 1 |
| Caínzos-Romero, T; Fernández-Fernández, FJ; Ferreira-González, L; Sesma, P | 1 |
| Eberlein, B; Gebhardt, E; Gilbertz, KP; Placzek, M; Przybilla, B | 1 |
| Abramowitz, Y; Arbel, Y; Banai, S; Berliner, S; Birati, EY; Deutsch, V; Finkelstein, A; Halkin, A; Herz, I; Keren, G; Kletzel, H | 1 |
| Goumas, C; Kesisoglou, F; Litou, C; Reppas, C; Vasdekis, V; Vertzoni, M; Xu, W | 1 |
| Hecht, S; Kuhl, A; Marshall, K; Odunayo, A; Price, J; Steiner, J; Tolbert, MK | 1 |
| D'Andrea, E; Desai, RJ; Feldman, WB; Lin, KJ; Liu, J; Pramod Umarje, S; Tesfaye, H; Wang, SV; Zabotka, LE | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Avdeef, A; Tam, KY | 1 |
| Giacomini, KM; Huang, Y; Khuri, N; Kido, Y; Kosaka, A; Morrissey, KM; Sali, A; Wittwer, MB; Zhang, X; Zur, AA | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
4 review(s) available for pantoprazole and famotidine
| Article | Year |
|---|---|
Pharmacokinetic optimisation in the treatment of gastro-oesophageal reflux disease.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Antacids; Benzimidazoles; Cimetidine; Cisapride; Domperidone; Famotidine; Gastroesophageal Reflux; Histamine H2 Antagonists; Humans; Lansoprazole; Metoclopramide; Nizatidine; Omeprazole; Pantoprazole; Piperidines; Proton Pump Inhibitors; Ranitidine; Sucralfate; Sulfoxides | 1996 |
Anaphylactic reaction to drugs commonly used for gastrointestinal system diseases: 3 case reports and review of the literature.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anaphylaxis; Anti-Ulcer Agents; Benzimidazoles; Famotidine; Female; Gastroesophageal Reflux; Gastrointestinal Diseases; Humans; Lansoprazole; Male; Middle Aged; Omeprazole; Pantoprazole; Ranitidine; Skin Tests | 2006 |
[Safety of proton pump inhibitors].
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Adult; Age Factors; Aged; Animals; Anti-Ulcer Agents; Cimetidine; Enzyme Inhibitors; Famotidine; Female; Fetus; Histamine H2 Antagonists; Humans; Lactation; Lansoprazole; Meta-Analysis as Topic; Nizatidine; Omeprazole; Pantoprazole; Pregnancy; Proton Pump Inhibitors; Proton-Translocating ATPases; Rabeprazole; Ranitidine; Safety; Time Factors | 2006 |
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
6 trial(s) available for pantoprazole and famotidine
| Article | Year |
|---|---|
Inhibition of pentagastrin-induced gastric acid secretion by intravenous pantoprazole: a dose-response study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adolescent; Adult; Anti-Ulcer Agents; Benzimidazoles; Dose-Response Relationship, Drug; Famotidine; Female; Gastric Acid; Humans; Infusions, Intravenous; Male; Middle Aged; Omeprazole; Pantoprazole; Pentagastrin; Proton Pump Inhibitors; Sulfoxides; Zollinger-Ellison Syndrome | 1999 |
A prospective randomized trial of either famotidine or pantoprazole for the prevention of bleeding after endoscopic submucosal dissection.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Dissection; Famotidine; Female; Gastric Mucosa; Gastrointestinal Hemorrhage; Gastroscopy; Humans; Male; Middle Aged; Pantoprazole; Postoperative Hemorrhage; Prospective Studies; Single-Blind Method; Stomach Neoplasms | 2007 |
Famotidine is inferior to pantoprazole in preventing recurrence of aspirin-related peptic ulcers or erosions.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Bacterial Agents; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Aspirin; Famotidine; Female; Follow-Up Studies; Gastrointestinal Hemorrhage; Helicobacter Infections; Histamine H2 Antagonists; Humans; Male; Middle Aged; Pantoprazole; Peptic Ulcer; Risk Factors; Secondary Prevention; Treatment Outcome | 2010 |
Platelet inhibitory effect of clopidogrel in patients treated with omeprazole, pantoprazole, and famotidine: a prospective, randomized, crossover study.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Aged; Aged, 80 and over; Aspirin; Chi-Square Distribution; Clopidogrel; Cross-Over Studies; Drug Interactions; Drug Resistance; Drug Therapy, Combination; Famotidine; Female; Histamine H2 Antagonists; Humans; Israel; Linear Models; Male; Middle Aged; Omeprazole; Pantoprazole; Platelet Aggregation; Platelet Aggregation Inhibitors; Platelet Function Tests; Prospective Studies; Proton Pump Inhibitors; Single-Blind Method; Ticlopidine; Time Factors; Treatment Outcome | 2013 |
Characteristics of the Human Upper Gastrointestinal Contents in the Fasted State Under Hypo- and A-chlorhydric Gastric Conditions Under Conditions of Typical Drug - Drug Interaction Studies.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Achlorhydria; Administration, Oral; Adult; Bile Acids and Salts; Buffers; Chlorides; Cross-Over Studies; Drinking; Drug Administration Schedule; Drug Interactions; Famotidine; Fasting; Gastric Acid; Gastric Mucosa; Gastrointestinal Contents; Greece; Healthy Volunteers; Histamine H2 Antagonists; Humans; Hydrogen-Ion Concentration; Male; Osmolar Concentration; Pantoprazole; Proton Pump Inhibitors; Suction; Surface Tension; Time Factors; Young Adult | 2016 |
Comparative analysis of the effect of IV administered acid suppressants on gastric pH in dogs.
Topics: Animals; Anti-Ulcer Agents; Cross-Over Studies; Dogs; Esomeprazole; Famotidine; Female; Hydrogen-Ion Concentration; Injections, Intravenous; Male; Pantoprazole | 2020 |
16 other study(ies) available for pantoprazole and famotidine
| Article | Year |
|---|---|
The novel proton pump inhibitor pantoprazole elevates intragastric pH for a prolonged period when administered under conditions of stimulated gastric acid secretion in the gastric fistula dog.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adenosine Triphosphatases; Animals; Benzimidazoles; Dogs; Famotidine; Gastric Acid; Gastric Fistula; Gastric Mucosa; Male; Omeprazole; Pantoprazole; Pentagastrin; Stomach; Sulfoxides | 1991 |
Effects of ranitidine, famotidine, pantoprazole, and omeprazole on intragastric pH in dogs.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Analysis of Variance; Animals; Benzimidazoles; Dogs; Dose-Response Relationship, Drug; Famotidine; Food Deprivation; Gastric Acidity Determination; Gastric Juice; Histamine H2 Antagonists; Hydrogen-Ion Concentration; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Ranitidine; Reference Values; Sulfoxides | 2005 |
Famotidine versus pantoprazole for preventing bleeding in the upper gastrointestinal tract of critically ill patients receiving mechanical ventilation.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Famotidine; Histamine H2 Antagonists; Humans; Middle Aged; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Respiration, Artificial; Retrospective Studies; Treatment Outcome | 2008 |
Bleeding in the upper part of the gastrointestinal tract due to stress ulcers.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Famotidine; Histamine H2 Antagonists; Humans; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Respiration, Artificial | 2008 |
Famotidine versus pantoprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Critical Illness; Famotidine; Histamine H2 Antagonists; Humans; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Respiration, Artificial | 2008 |
Skeptical that pantoprazole dose can prevent bleeding.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Anti-Ulcer Agents; Famotidine; Histamine H2 Antagonists; Humans; Pantoprazole; Peptic Ulcer Hemorrhage; Proton Pump Inhibitors; Respiration, Artificial | 2008 |
Effects of pantoprazole on ulcer healing delay associated with NSAID treatment.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Acetic Acid; Animals; Anti-Inflammatory Agents, Non-Steroidal; Anti-Ulcer Agents; Blotting, Western; Caspase 3; Disease Models, Animal; Famotidine; Gastric Acid; Male; Oxidative Stress; Pantoprazole; Proliferating Cell Nuclear Antigen; Proton Pump Inhibitors; Rats; Stomach Ulcer; Wound Healing | 2009 |
Oral sulfasalazine as a clinical BCRP probe substrate: pharmacokinetic effects of genetic variation (C421A) and pantoprazole coadministration.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Adult; Arylamine N-Acetyltransferase; ATP Binding Cassette Transporter, Subfamily G, Member 2; ATP-Binding Cassette Transporters; Biotransformation; Chromatography, High Pressure Liquid; Cross-Over Studies; Enzyme Inhibitors; Famotidine; Gastric Mucosa; Genotype; Humans; Hydrogen-Ion Concentration; Male; Middle Aged; Neoplasm Proteins; Pantoprazole; Pharmacogenetics; Polymorphism, Genetic; Proton Pump Inhibitors; Spectrophotometry, Ultraviolet; Sulfasalazine; Young Adult | 2010 |
Intermittent use of pantoprazole and famotidine in severe hypomagnesaemia due to omeprazole.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Aged; Anti-Ulcer Agents; Famotidine; Histamine H2 Antagonists; Humans; Magnesium Deficiency; Male; Omeprazole; Pantoprazole; Proton Pump Inhibitors; Treatment Outcome | 2010 |
In vitro evaluation of phototoxic properties of proton pump inhibitors, H2-receptor antagonists and statins.
Topics: 2-Pyridinylmethylsulfinylbenzimidazoles; Ascorbic Acid; Cimetidine; Erythrocytes; Famotidine; Hemolysis; Histamine H2 Antagonists; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Lansoprazole; Lovastatin; Nizatidine; Omeprazole; Pantoprazole; Pravastatin; Proton Pump Inhibitors; Ranitidine; Ultraviolet Rays | 2012 |
Gastrointestinal prophylaxis for COVID-19: an illustration of severe bias arising from inappropriate comparators in observational studies.
Topics: COVID-19; Famotidine; Humans; Omeprazole; Pantoprazole; Proton Pump Inhibitors | 2022 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
How well can the Caco-2/Madin-Darby canine kidney models predict effective human jejunal permeability?
Topics: Animals; Disease Models, Animal; Dogs; Humans; Jejunal Diseases; Kidney Diseases; Models, Biological; Permeability; Porosity; Regression Analysis | 2010 |
Discovery of potent, selective multidrug and toxin extrusion transporter 1 (MATE1, SLC47A1) inhibitors through prescription drug profiling and computational modeling.
Topics: Computer Simulation; Fluorescent Dyes; Organic Cation Transport Proteins; Prescription Drugs | 2013 |